These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29045127)

  • 21. Particle size-dependent triggering of accelerated blood clearance phenomenon.
    Koide H; Asai T; Hatanaka K; Urakami T; Ishii T; Kenjo E; Nishihara M; Yokoyama M; Ishida T; Kiwada H; Oku N
    Int J Pharm; 2008 Oct; 362(1-2):197-200. PubMed ID: 18586076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PEGylated Liposomes Accumulate in the Areas Relevant to Skin Toxicities
    Li Y; Lofchy L; Wang G; Gaikwad H; Fujita M; Simberg D
    ACS Nano; 2022 Apr; 16(4):6349-6358. PubMed ID: 35343675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular targeting of doxorubicin using cationic liposomes.
    Wu J; Lee A; Lu Y; Lee RJ
    Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice.
    Hashimoto Y; Shimizu T; Abu Lila AS; Ishida T; Kiwada H
    Biol Pharm Bull; 2015; 38(3):417-24. PubMed ID: 25757923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theranostic Imaging May Vaccinate against the Therapeutic Benefit of Long Circulating PEGylated Liposomes and Change Cargo Pharmacokinetics.
    Børresen B; Henriksen JR; Clergeaud G; Jørgensen JS; Melander F; Elema DR; Szebeni J; Engelholm SA; Kristensen AT; Kjær A; Andresen TL; Hansen AE
    ACS Nano; 2018 Nov; 12(11):11386-11398. PubMed ID: 30372038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel effects with polyethylene glycol modified pharmaceuticals.
    Yowell SL; Blackwell S
    Cancer Treat Rev; 2002 Apr; 28 Suppl A():3-6. PubMed ID: 12173408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotargeting of liposomes containing lipophilic antitumor prodrugs.
    Mori A; Kennel SJ; Huang L
    Pharm Res; 1993 Apr; 10(4):507-14. PubMed ID: 8483832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.
    Ishida T; Harada M; Wang XY; Ichihara M; Irimura K; Kiwada H
    J Control Release; 2005 Jul; 105(3):305-17. PubMed ID: 15908032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent.
    Lozano N; Al-Ahmady ZS; Beziere NS; Ntziachristos V; Kostarelos K
    Int J Pharm; 2015 Mar; 482(1-2):2-10. PubMed ID: 25445515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal monitoring of skin accumulation of nanocarriers and biologicals with fiber optic near infrared fluorescence spectroscopy (FONIRS).
    Griffin JI; Benchimol MJ; Simberg D
    J Control Release; 2017 Feb; 247():167-174. PubMed ID: 28069552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug.
    Lu WL; Qi XR; Zhang Q; Li RY; Wang GL; Zhang RJ; Wei SL
    J Pharmacol Sci; 2004 Jul; 95(3):381-9. PubMed ID: 15272215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microfluidic preparation of drug-loaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration.
    Dong YD; Tchung E; Nowell C; Kaga S; Leong N; Mehta D; Kaminskas LM; Boyd BJ
    J Liposome Res; 2019 Mar; 29(1):1-9. PubMed ID: 29020849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy.
    Pasut G; Paolino D; Celia C; Mero A; Joseph AS; Wolfram J; Cosco D; Schiavon O; Shen H; Fresta M
    J Control Release; 2015 Feb; 199():106-13. PubMed ID: 25499917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved anti-breast cancer activity by doxorubicin-loaded super stealth liposomes.
    Paolino D; d'Avanzo N; Canato E; Ciriolo L; Grigoletto A; Cristiano MC; Mancuso A; Celia C; Pasut G; Fresta M
    Biomater Sci; 2024 Jul; 12(15):3933-3946. PubMed ID: 38940612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
    Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
    Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes.
    Hsieh YC; Wang HE; Lin WW; Roffler SR; Cheng TC; Su YC; Li JJ; Chen CC; Huang CH; Chen BM; Wang JY; Cheng TL; Chen FM
    Theranostics; 2018; 8(11):3164-3175. PubMed ID: 29896310
    [No Abstract]   [Full Text] [Related]  

  • 38. An efficient PEGylated liposomal nanocarrier containing cell-penetrating peptide and pH-sensitive hydrazone bond for enhancing tumor-targeted drug delivery.
    Ding Y; Sun D; Wang GL; Yang HG; Xu HF; Chen JH; Xie Y; Wang ZQ
    Int J Nanomedicine; 2015; 10():6199-214. PubMed ID: 26491292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
    Shroff K; Kokkoli E
    Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes.
    Peretz Damari S; Shamrakov D; Varenik M; Koren E; Nativ-Roth E; Barenholz Y; Regev O
    Int J Pharm; 2018 Aug; 547(1-2):648-655. PubMed ID: 29913218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.